- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02265588
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). (HAPPY-IBD)
Reducing Symptoms of Depression and Anxiety in Adolescents With Inflammatory Bowel Disease in Order to Improve Quality of Life and the Clinical Course of Disease.
Study Overview
Status
Intervention / Treatment
Detailed Description
- Objective: The primary objective is to determine the efficacy of a disease specific cognitive behavioral therapy program in adolescents with IBD and increased symptoms of depression or anxiety on reducing symptoms of depression. Secondary objectives are to assess the effect of the CBT program on a) the clinical course of disease b) reducing symptoms of anxiety, and c) improving quality of life. We also aim to identify psychosocial and medical factors that predict or moderate the treatment response to CBT in adolescent with IBD.
- Study design: The presented study is a multicenter randomized controlled trial (RCT), involving CBT versus care as usual (CAU), in young IBD patients with increased symptoms of self-reported depression or anxiety. There will be three follow-up moments, after 3 months or after the intervention and after 6 and 12 months.
- Study population: Patients with IBD between 10-25 years and increased symptoms of depression or anxiety. We aim to include 100 patients, from which 50 patients will be randomized to the treatment condition (CBT and CAU) and 50 to the control group (CAU).
- Intervention: A disease specific CBT program called PASCET-PI. The control group (CAU),will receive routine medical treatment (thus no additional psychosocial intervention) and will maintain their regular follow up visits at the gastroenterologist every 3 months.
- Main study endpoints: Main outcome is reduction in symptoms of depression. Important secondary outcomes are the presence of clinical relapse and reduction of symptoms of anxiety. Other secondary outcomes, amongst others, are IBD activity scores, quality of life, psychosocial functioning, and adherence to medical treatment.
- Nature and extent of the burden and risks associated with participation, benefit and group relatedness: At first, patients with IBD 10 -25 years of age will be screened for symptoms of depression and anxiety at T1. Patients with increased symptoms of self-reported depression or anxiety (scoring above an age and gender specific cut-off score for increased depressive or anxiety symptoms) are asked to participate in the RCT. For all included patients, 4 study visits will take place, these will be combined with regular checkup visits at the gastroenterologist. Questionnaires will need to be filled in online, taking approximately 1.5 hour per assessment for patients and approximately 1 hour per assessment for parents. At baseline a psychiatric assessment interview will be executed by an independent research clinical psychologist by phone (20 minutes). The same research clinical psychologist will conduct a short psychiatric assessment interview at the follow up visits 10minutes). At baseline and after 3 months blood samples (when patients undergo routine venous punctures) will be drawn.
For patients in the CBT group, 13 sessions (6 outpatient sessions, 7 by phone) and three parental sessions will take place in a hospital close to their home. Our study population consists of adolescents and young adults with IBD, as this is a specific group with high reported symptoms of depression and anxiety, therefore they will most likely benefit from the intervention. The risks associated with participation can be considered negligible and the burden minimal. For the time investment of completing the questionnaires participants will receive an incentive of 25 euro after the final assessment, which will be communicated at the start.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nederland
-
Rotterdam, Nederland, Netherlands, 3015CN
- Erasmus Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between 10-25 years with diagnosed IBD
- Informed consent or assent by patients and (if necessary) parents
Exclusion Criteria:
- IBD patients with parental report of mental retardation
- IBD patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety
- No mastery of the Dutch language
- IBD patients with diagnosed: Bipolar disorder, Schizophrenia/psychotic disorder, Autism spectrum disorders, Obsessive-compulsive disorder, Posttraumatic stress disorder/Acute stress disorder, or Substance use disorder
- Physician reported substance abuse (alcohol, drugs) in the past month
- Clinician reported Selective mutism
- IBD patients already participating in an (psychological of psychopharmacological) intervention study
- IBD patients who received 8 sessions of manualized cognitive behavioral therapy last year
- current psychological treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Care as usual
Care as usual means receiving their regular medical care.
This consists of the regular follow up visits at the gastroenterologist every 3 months.
|
|
Experimental: Cognitive Behavioral Therapy
The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI.
The therapy sessions will be performed by trained psychologist.
|
A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in symptoms of depression (change from baseline)
Time Frame: 12 weeks and 52 weeks
|
Measured by the Child Depression Inventory (CDI (10-17 years), Beck Depression Inventory (BDI; 18-25 years) and severity rating (interview): the Children's Depression Rating Scale (CDRS;10-12 years) and Adolescent Depression Rating Scale(ADRS;13-20 years), HAM-D: Hamilton Depression Rating Scale (21-25 year)
|
12 weeks and 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in symptoms of anxiety (change from baseline)
Time Frame: 12 weeks and 52 weeks
|
Measured by SCARED-NL: Screen for Anxiety Related Emotional Disorders (10-20 years), Hospital Anxiety and Depression Scale (HADS; 21-25 year) and severity rating by Pediatrix Anxiety Rating Scale (PARS) (10-20 years) ,Hamilton Anxiety Rating (HAM-A)(21-25 year)
|
12 weeks and 52 weeks
|
General Quality of Life
Time Frame: 12 weeks and 52 weeks
|
Assessed by the Child Health Related Quality of Life (TACQOL) (10-15 years) Adult Health Related Quality of Life (TAAQOL, 16-25 years)
|
12 weeks and 52 weeks
|
Social Skills
Time Frame: 12 weeks
|
Assessed by Social Skills Rating System (SSRS) (10-20years) Novotni SSC: Social Skills Checklist (21-25 year)
|
12 weeks
|
Social competence
Time Frame: 12 weeks
|
Assessed by Youth Self Report (YSR) / Adult Self Report (ASR)
|
12 weeks
|
Disease specific quality of life
Time Frame: 12 weeks and 52 weeks
|
Assessed by the IMPACT-III-NL (10-20years) IBDQ: Inflammatory Bowel Disease Questionnaire (21-25 year)
|
12 weeks and 52 weeks
|
Disease Activity
Time Frame: 52 weeks
|
Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) (10-20 years) Pediatric Crohn's Disease Activity Index (PCDAI) (10-20 years) CDAI: Crohn's Disease Activity Index (21-25 years) Partial Mayo Score (21-25 years) Physician Global Assessment (PGA)
|
52 weeks
|
Clinical relapse (number of flares)
Time Frame: 52 weeks
|
10-20 Years: Relapse for CD is defined as PCDAI>30 or an increase of>15 points and intensification of medical treatment. Relapse for UC is defined as PUCAI > 34 or an increase of ≥20 points for UC and intensification of medical treatment. 21-25 years: Partial Mayo score of 3 or higher with intensification of medical treatment Or CDAI≥ 150 and an increase in baseline CDAI score of ≥ 70 points and intensification of medical treatment |
52 weeks
|
Maintaining remission
Time Frame: 52 weeks
|
Remission is defined as PCDAI < 10 for CD and PUCAI < 10 for UC.
CDAI < 150 and Mayo score ≤2 with no individual subscore > 1
|
52 weeks
|
Medication Usage (change from baseline)
Time Frame: 52 weeks
|
Type and dosage of medication
|
52 weeks
|
Necessity of surgical intervention
Time Frame: 52 weeks
|
Description of type and extent of surgical intervention
|
52 weeks
|
Adherence to therapy (change from baseline)
Time Frame: 52 weeks
|
Assessed by the Morisky Medical Adherence Scale (MASS-8)
|
52 weeks
|
Health care utilization (change from baseline)
Time Frame: 52 weeks
|
Assessed by standardized items derived from the questionnaires and Report of the treating physician.
|
52 weeks
|
Inflammatory markers
Time Frame: baseline and 12, 24 and 52 weeks
|
Inflammatory markers will be measured at all time points (baseline and after 3,6,12 months) Inflammatory markers like BSE, CRP, faecal calprotectin
|
baseline and 12, 24 and 52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease perception (change from baseline)
Time Frame: 12 weeks
|
Assesses by the Brief Illness Perceptions Questionnaire (B-IPQ)
|
12 weeks
|
Cognitive coping styles (change from baseline)
Time Frame: 12 weeks
|
Assesses by the Cognitive Emotion Regulation Questionnaire (CERQ)
|
12 weeks
|
Quality of sleep (change from baseline)
Time Frame: 12 weeks
|
Assesses by the Sleep Self-Report (SSR) (10-20 years) PSQI: Pittsburgh Sleep Quality Index (21-25 year)
|
12 weeks
|
Demographic factors
Time Frame: 12 weeks
|
Assesses by the Rotterdam's quality of life interview
|
12 weeks
|
Parental anxiety and depression
Time Frame: 12 weeks
|
Assesses by the Depression, Anxiety and Stress Scale (DASS-21)
|
12 weeks
|
Life Events
Time Frame: 12 weeks
|
Assesses by the Life events questionnaire from CERQ
|
12 weeks
|
Family Functioning (change from baseline)
Time Frame: 12 weeks
|
Assesses by the Family Assessment Device (FAD)
|
12 weeks
|
Disease phenotypes
Time Frame: 52 weeks
|
Assessed by the Paris Classification
|
52 weeks
|
Treatment Strategy
Time Frame: 52 weeks
|
The treatment strategy, type and dosage of medication will be extracted from the medical file and report of the treating physician.
|
52 weeks
|
White blood cell RNA expression profiles (change from baseline)
Time Frame: 12 weeks
|
Assessing immune status is done by analyzing gene expression profiles in peripheral blood leukocytes.
This will be performed
|
12 weeks
|
Immunological activity in peripheral blood mononuclear cells (PBMC)
Time Frame: 12 weeks
|
A blood sample will be taken in all patients included within the Erasmus MC for determination of responsiveness of peripheral blood lymphocytes before and directly after the intervention
|
12 weeks
|
Irritable bowel syndrome -like symptoms
Time Frame: 12 months
|
Assessed by the ROME III diagnostic criteria for IBS in pediatric IBD patients
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Johanna C. Escher, PhD, MD, Erasmus Medical Centre
Publications and helpful links
General Publications
- Szigethy E, Kenney E, Carpenter J, Hardy DM, Fairclough D, Bousvaros A, Keljo D, Weisz J, Beardslee WR, Noll R, DeMASO DR. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry. 2007 Oct;46(10):1290-1298. doi: 10.1097/chi.0b013e3180f6341f.
- Thompson RD, Craig A, Crawford EA, Fairclough D, Gonzalez-Heydrich J, Bousvaros A, Noll RB, DeMaso DR, Szigethy E. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep;19(3):329-37. doi: 10.1007/s10880-012-9301-8.
- Stapersma L, van den Brink G, van der Ende J, Szigethy EM, Groeneweg M, de Bruijne FH, Hillegers MHJ, Escher JC, Utens EMWJ. Psychological Outcomes of a Cognitive Behavioral Therapy for Youth with Inflammatory Bowel Disease: Results of the HAPPY-IBD Randomized Controlled Trial at 6- and 12-Month Follow-Up. J Clin Psychol Med Settings. 2020 Sep;27(3):490-506. doi: 10.1007/s10880-019-09649-9.
- Stapersma L, van den Brink G, van der Ende J, Szigethy EM, Beukers R, Korpershoek TA, Theuns-Valks SDM, Hillegers MHJ, Escher JC, Utens EMWJ. Effectiveness of Disease-Specific Cognitive Behavioral Therapy on Anxiety, Depression, and Quality of Life in Youth With Inflammatory Bowel Disease: A Randomized Controlled Trial. J Pediatr Psychol. 2018 Oct 1;43(9):967-980. doi: 10.1093/jpepsy/jsy029. Erratum In: J Pediatr Psychol. 2020 Aug 1;45(7):825.
- van den Brink G, Stapersma L, El Marroun H, Henrichs J, Szigethy EM, Utens EM, Escher JC. Effectiveness of disease-specific cognitive-behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD). BMJ Open Gastroenterol. 2016 Mar 2;3(1):e000071. doi: 10.1136/bmjgast-2015-000071. eCollection 2016.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Digestive System Diseases
- Pathologic Processes
- Mood Disorders
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Depression
- Depressive Disorder
- Ulcer
- Inflammatory Bowel Diseases
- Anxiety Disorders
- Crohn Disease
- Intestinal Diseases
- Colitis
- Colitis, Ulcerative
Other Study ID Numbers
- NL49147.078.14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Federal Research Center of Fundamental and Translational...CompletedDepression Moderate | Depression MildRussian Federation
Clinical Trials on Cognitive behavioral therapy
-
Eleos HealthMissouri Department of Mental HealthCompletedMood Disorders | Anxiety DisordersUnited States
-
Regionsenter for barn og unges psykiske helseThe Research Council of NorwayCompletedGeneralized Anxiety Disorder | Social Phobia | Separation Anxiety DisorderNorway
-
Claremont McKenna CollegeUniversity of California, Los AngelesCompleted
-
University of South FloridaObsessive Compulsive FoundationCompletedObsessive Compulsive Disorder | Stepped Care Cognitive Behavioral TherapyUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
University of RochesterNational Institute of Nursing Research (NINR)CompletedDepression | Sleep | Stress Disorders, Post-TraumaticUnited States
-
University of PittsburghWithdrawnPsychosis | Prodromal Symptoms | Prodromal Stage | Prodromal StatesUnited States
-
Duke UniversityCompleted
-
The University of Texas Health Science Center at...59th Medical Wing; Brooke Army Medical Center; South Texas Veterans Health Care...CompletedCombat Disorders | Post-Traumatic Stress Disorders | Stress DisordersUnited States
-
University of PittsburghCompletedDepression | Anxiety | Sickle Cell DiseaseUnited States